Research Analysts’ Updated EPS Estimates for January, 11th (ABBV, AEHR, AEIS, AFLYY, AJMPF, ALBO, ALDR, ANFI, ANIOY, APPS)

Research Analysts’ updated eps estimates for Thursday, January 11th:

AbbVie (NYSE:ABBV) was given a $84.00 target price by analysts at BMO Capital Markets. The firm currently has a hold rating on the stock.

Aehr Test Systems (NASDAQ:AEHR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $3.25 price target on the stock. According to Zacks, “Aehr Test Systems develops, manufactures and sells systems which are designed to reduce the cost of testing DRAMs and other memory devices, perform reliability screening or burn-in of complex logic and memory devices, and enable IC manufacturers to perform test and burn-in of bare die. Leveraging its expertise as a long-time leading provider of burn-in equipment, with over 2,000 systems installed worldwide, the Company has developed and introduced two innovative product families, the MTX system and the DiePak-Registered Trademark- carrier. “

Advanced Energy Industries (NASDAQ:AEIS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $76.00 target price on the stock. According to Zacks, “Advanced Energy is a global leader in the development and support of technologies critical to high-technology, high-growth manufacturing processes used in the production of semiconductors, flat panel displays, data storage products, solar cells, architectural glass, and other advanced product applications. Leveraging a diverse product portfolio and technology leadership, Advanced Energy creates solutions that maximize process impact, improve productivity and lower the cost of ownership for its customers. This portfolio includes a comprehensive line of technology solutions in power, flow, thermal management, and plasma and ion beam sources for original equipment manufacturers and end-users around the world. Advanced Energy operates in regional centers in North America, Asia and Europe and offers global sales and support through direct offices, representatives and distributors, “

Air France KLM (OTCMKTS:AFLYY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $18.00 target price on the stock. According to Zacks, “AIR FRANCE-KLM is an airline company. The Company’s core business is passenger transport, cargo transport, and aircraft maintenance services. The Group is the world leader in terms of international passenger traffic; and its cargo activity (not including integrators) and is one of the world’s major maintenance service providers. The Group structure is simple: a holding company with two airline subsidiaries. Air France-KLM has established a set of clearly defined commitments to ensure that its strategy of profitable growth goes hand in hand with environmental quality and social progress. “

Ashmore Group (OTCMKTS:AJMPF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Ashmore Group plc is an emerging market investment manager. It invests in the public equity and fixed income markets. Ashmore Group plc is based in London, United Kingdom. “

Albireo Pharma (NASDAQ:ALBO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “

Alder BioPharmaceuticals (NASDAQ:ALDR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “

Amira Nature Foods (NYSE:ANFI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $4.50 price target on the stock. According to Zacks, “Amira Nature Foods Ltd. provides packaged Indian specialty rice. The Company sells Basmati rice, premium long-grain rice under their flagship Amira brand as well as under other third party brands. It participates across the entire rice supply chain from the procurement of paddy to its storage, aging, processing into rice, packaging, distribution and marketing. Amira Nature Foods Ltd. is headquartered in Dubai, United Arab Emirates. “

Acerinox (OTCMKTS:ANIOY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Acerinox, S.A. is engaged in production and selling stainless steel. The Company also offers slabs, billets, black coils, sheets, angles and bars. It operates primarily in Spain, USA, South Africa and Malaysia. Acerinox, S.A. is headquartered in Madrid, Spain. “

Digital Turbine (NASDAQ:APPS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Digital Turbine Inc. offers products and solutions for mobile operators, device OEMs and third parties. The company’s product include DT Ignite(TM), a mobile device management solution with targeted app distribution capabilities, DT IQ(TM), a customized user experience and app discovery tool, DT Marketplace(TM), an application and content store and DT Pay(TM), a content management and mobile payment solution. It operates primarily in Berlin, Singapore and Sydney. Digital Turbine, Inc., formerly known as Mandalay Digital Group, Inc., is headquartered in Austin, Texas. “

Approach Resources (NASDAQ:AREX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Approach Resources Inc. is an independent energy company engaged in the exploration, development, exploitation, production and acquisition of unconventional natural gas and oil properties onshore in the United States and Western Canada. The Company focuses its growth efforts primarily on finding and developing natural gas reserves in known tight gas sands and shale areas. The Company currently operates in Texas, New Mexico and Kentucky and has a non-operating interest in Western Canada. “

Activision Blizzard (NASDAQ:ATVI) was given a $75.00 price target by analysts at Wedbush. The firm currently has a buy rating on the stock.

Continental Resources (NYSE:CLR) had its price target increased by Barclays PLC from $53.00 to $58.00. The firm currently has an overweight rating on the stock.

Neuralstem (NASDAQ:CUR) had its target price reduced by S&P Equity Research from $2.26 to $1.91.

Domino's Pizza (NYSE:DPZ) had its price target raised by Nomura to $230.00. They currently have a buy rating on the stock.

Domino's Pizza (NYSE:DPZ) had its price target raised by Deutsche Bank AG to $220.00. The firm currently has a buy rating on the stock.

First Commonwealth Financial (NYSE:FCF) had its hold rating reiterated by analysts at Boenning Scattergood. The analysts wrote, “We contend the discount is unwarranted, but believe it is not large enough to change our rating at present.””

Alphabet (NASDAQ:GOOG) had its target price raised by Piper Jaffray Companies to $1,300.00. The firm currently has an overweight rating on the stock.

Harsco (NYSE:HSC) had its target price increased by Argus to $24.00. They currently have a buy rating on the stock.

Kering (EPA:KER) was given a €400.00 ($476.19) price target by analysts at Sanford C. Bernstein. The firm currently has a neutral rating on the stock.

Novavax (NASDAQ:NVAX) had its price target raised by Ladenburg Thalmann Financial Services to $2.50. Ladenburg Thalmann Financial Services currently has a buy rating on the stock.

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit